Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease

Thrombosis and Haemostasis

Volumn 77, Issue 4, 1997, Pages 730-734

  Catto, Andrew J ^a   Carter, Angela M ^a   Stickland, Max ^a   Bamford, John M ^b   Davies, J Andrew ^a   Grant, Peter J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADULT; AGED; ANAMNESIS; ARTICLE; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; SMOKING; STROKE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030966138     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656042     Document Type: Article

References (29)

1. Ridker PM, Hennekens CH. Hemostatic risk factors for coronary heart disease. Circulation 1991; 83: 1098-100.
2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 2: 533-7.
3. Hamsten A, Walldius G, De Faire U, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
4. Brockmann MJ, Schwendemann G, Stief TW. Plasminogen activator inhibitor in acute stroke. Mol Chem Neuropathol 1991; 14: 143-50.
5. Margaglione M, Di Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arter Thromb 1994; 14: 1741-5.
6. Glueck CJ, Rorick MH, Schmerler M, Anthony J, Feibel J, Bashir M, Glueck HI, Stroop D, Wang Y, Tracy TM. Hypofibrinolytic factors and atherogenic risk factors for stroke. J Lab Clin Med 1995; 125: 319-25.
7. Kempter B, Peinemann A, Biniasch O, Haberl RL. Decreased fibrinolytic stimulation by a short-term venous occlusion test in patients with cerebrovascular disease. Thromb Res 1995; 79: 363-8.
8. Fisher M, Francis R. Altered coagulation in cerebral ischaemia. Platelet, thrombin and plasmin activity. Arch Neurol 1990; 47: 1075-9.
9. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-3.
10. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arter Thromb 1991; 11: 183-90.
11. Eriksson P, Kallin B, Van'T Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Nat Acad Sci USA 1995; 92: 1851-5.
12. Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-7.
13. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42.
14. Hantano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54: 541-53.
15. Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. British Journal of Preventive and Social Medicine 1977; 31: 42-8.
16. WHO MONICA Project. WHO MONICA Project: assessing CHD mortality and morbidity. Int J Epidemiol 1989; 18: S38-45.
17. Bamford J, Sandercock P, Dennis M, Burn J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-6.
18. Mansfield MW, Stickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994; 71: 731-6.
19. Kruithof E. Plasminogen activators: a review. Enzyme 1988; 40: 113-21.
20. Juhan-Vague I, Aillaud MF, De Cock FPC, Arnaud C, Serradimigni A, Collen P, Davidson JF, Donati MB, Coccheri S (eds). Progress in fibrinolysis. Edinburgh: Churchill Livingstone, 1985; The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant. pp 146-9.
21. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Nat Acad Sci USA 1992; 89: 6998-7002.
22. Anonymous. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 8-17.
23. Dennis MS, Burn JPS, Sandercock PA, Bamford J, Wade DT, Warlow CP. Long term survival after first-ever stroke: The Oxfordshire Community Stroke Project. Stroke 1993; 24: 796-800.
24. Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-5.
25. Aronson DC, Ruys T, van Bockel JH. A prospective study of risk factors in young adults with arterial occlusive disease. Eur J Vasc Surg 1989; 3: 227-32.
26. Falk G, Almquist A, Nordenhern A, Svensson H, Wiman B. Allele specific PCR for the detection of a sequence polymorphism in the promoter region of the plasminogen-activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995; 9 (3): 170-4
27. Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscler Thromb Vasc Biol 1996; In press.
28. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-41.
29. Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in Non-Insulin-Dependent Diabetes. Thromb Haemost 1995; 74: 1032-4.